Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis

US9399061B2 · kind B2 · utility

Assignee

• AbbVie Biotechnology Ltd. · BM

Inventors

• Hartmut Kupper · Mutterstadt, DE
• Jeffrey D. Kent · Deerfield, US
• Mary A. Cifaldi · Gurnee, US
• John Lance Perez · Doylestown, US
• Gerd-Reudiger Burmester · Berlin, DE
• Philip Mease · Seattle, US
• Daniel J. Lovell · Cincinnati, US
• Edward Keystone · Toronto, CA
• Arthur Kavanaugh · San Diego, US

Key dates

• Filing date: Apr 10, 2007
• Grant date: Jul 26, 2016
• Expiry date: Apr 10, 2027

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.